Intravenous methylprednisolone for multiple sclerosis in relapse.
AUTOR(ES)
Barnes, M P
RESUMO
A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1028218Documentos Relacionados
- T lymphocyte-derived demyelinating activity in multiple sclerosis patients in relapse.
- Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone.
- Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.
- Methylprednisolone therapy in multiple sclerosis.
- Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.
